CalmiGo

Improving speed and accuracy in Alzheimer’s patients

Latest articles

The Sheekey Science Show – Aging Clocks

Aging clocks - how to measure biological age. I hope you have some time on you hands as today we will talk all about aging...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

Over a third of Generation X have multiple health problems

More than one in three British adults are suffering from two or more chronic health conditions in middle age, such as recurrent back problems,...

Forget the arms race – it’s time for a longevity race

Professor Andrew Scott outlines how society needs to change in order to capitalise on multi-trillion dollar longevity dividend. Last week, we brought you the views...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...
Seno

Editor's picks

The Sheekey Science Show – Aging Clocks

Aging clocks - how to measure biological age. I hope you have some time on you hands as today we will talk all about aging...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

Over a third of Generation X have multiple health problems

More than one in three British adults are suffering from two or more chronic health conditions in middle age, such as recurrent back problems,...
CalmiGo

Click the globe for translations.

Phase 2a study of patients with Alzheimer’s or Parkinson’s finds that ANVS401 treatment leads to significant improvement in speed and accuracy.

Annovis Bio Inc, a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, has announced that in a test that measures speed, AD and PD patients both respond with a statistically significant increase in correctly-coded fields after 25 days of treatment with ANVS401. The test was part of the company’s ongoing Phase 2a study in AD and PD patients.

Longevity.Technology: Alzheimer’s and Parkinson’s are both devastating neurological diseases, with large numbers of researchers working on diagnosing and delaying them. Headquartered in Berwyn, Pennsylvania, Annovis Bio is a clinical-stage, drug platform company that is in the unusual position of developing a drug for Alzheimer’s and Parkinson’s that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. Annovis expects its treatment to improve memory loss and dementia associated with Alzheimer’s, as well as body and brain function in Parkinson’s. Annovis has two ongoing Phase 2a studies: one in Alzheimer’s patients and one in both Alzheimer’s and Parkinson’s patients. 

“Our hypothesis states that neurodegenerative diseases, such as AD and PD have many commonalities and that in both diseases nerve cells die through similar pathways,” said Annovis Bio CEO Maria Maccecchini, PhD. “That is why we designed a double study, where we are measuring the same markers of the toxic cascade in both diseases. We also measured the coding scale of the WAIS test in both patient groups.”

The WAIS Coding Scale measures visual-motor dexterity, associative nonverbal learning, and nonverbal short-term memory. It measures fine-motor dexterity, speed, accuracy and ability to manipulate a pencil and perceptual organization.

Annovis Bio found that speed and accuracy was increased in both patient populations of its Phase 2a study, whether the comparison was made between the same patients before and after treatment or between the placebo and ANVS401 treated groups at 25 days. These data are from the first 14 AD and the first 14 PD patients in the study.

Parkinson’s disease – comparison between the treated group with 80 mg/day of ANVS401 at baseline before treatment and after 25 days on treatment and between placebo and treated group at 25 days in the rapid coding test. At 25 days the speed and accuracy of the treated group is faster than at baseline and the patients on average coded 6.1 more correct fields (p<0.05).  Also, at 25 days placebo performs worse than drug treated (p<0.05). To summarize the PD results, the two graphs show that while the placebo gets worse, the treated group gets faster.

Alzheimer’s disease – comparison between the treated group with 80 mg/day of ANVS401 at baseline before treatment and after 25 days on treatment and between placebo and treated group at 25 days in the rapid coding test. At 25 days the speed of the treated group is faster than at baseline and the patients on average coded 6.6 more correct fields (p<0.05).  Also, at 25 days placebo performs worse than drug treated (trend). To summarize the AD results, the two graphs show that while the placebo gets slightly better, the treated group gets much faster.

“This is one additional piece of information that confirms the data from our Phase 2a study and shows that ANVS401 is efficacious in both AD and PD,” said Dr Maccecchini.

Image courtesy of Dr Maccecchini

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
CalmiGo

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
Seno

Related articles

A pawsitive take in Alzheimer’s disease modelling

As purr-plexing as it may seem, cats may provide key answers in the study of dementia and Alzheimer’s disease. As we get older, our brain...

Reader Poll: just what does your future look like?

Your future is getting inexorably nearer – but will that be in high-tech comfort in your own home, down the road in a state-of-the-art...

Gerostate passes crowdfunding goal for antiaging drug platform

Longevitytech.fund joins investment round as Buck Institute start-up continues crowdfunding campaign to move antiaging drug candidates into mammalian studies. With around two weeks still remaining...

Scientists reverse age-related memory loss in mice

Scientists have successfully reversed age-related memory loss in mice – discovery could lead to the development of treatments to prevent memory loss in people...

Longevity senotherapeutics report: Insilico Medicine

Insilico – on a mission to accelerate senescence drug discovery and development by continuously inventing and deploying new AI technologies. Over the coming weeks, we...
Seno